1623 results for "LSD"
Transcriptome Fingerprints Distinguish Hallucinogenic and Nonhallucinogenic 5-Hydroxytryptamine 2A Receptor Agonist Effects in Mouse Somatosensory Cortex
Journal of Neuroscience – October 01, 2003
Summary
Hallucinogens like Lysergic acid diethylamide (LSD) induce distinct brain responses. Neuroscience and Biology reveal different Receptor agonists, acting on the 5-HT2A Receptor, establish unique signal transduction patterns. A Pharmacology and Cell biology transcriptome assay showed distinct fingerprints in human embryonic kidney 293 cells. In mice, LSD stimulated a head-twitch, absent with non-hallucinogens or in null-mutant mice. Unique somatosensory system transcriptome changes link specific drug effects (Psychedelics and Drug Studies) to Receptor Mechanisms and Signaling, influencing Behavior.
Abstract
Most neuropharmacological agents and many drugs of abuse modulate the activity of heptahelical G-protein-coupled receptors. Although the effects of...
Hallucinogen use in the United States, 2021-2023: Diverging trends and subgroup patterns.
Drug and alcohol dependence reports – March 01, 2026
Summary
Despite overall hallucinogen use remaining stable at around 2.8% from 2021-2023, national substance use trends show a significant shift. Epidemiology data from ages 12+ reveal LSD use declined from 0.88% to 0.58%, while ketamine use, another psychedelic, increased from 1.61% to 1.91%. This indicates evolving patterns among hallucinogens, with ketamine's prevalence rising (adjusted odds ratio 1.11 annually) as LSD's falls (adjusted odds ratio 0.83 annually). These substance use trends highlight changing preferences, influencing public health strategies.
Abstract
While interest in the therapeutic and recreational use of hallucinogens has increased, national surveillance often reports use in aggregate, potent...
Applying an Extended Version of the Theory of Planned Behavior to Illicit Drug Use Among Students1
Journal of Applied Social Psychology – August 01, 2003
Summary
Intentions to use illicit drugs like LSD, amphetamine, cannabis, and ecstasy can be predicted effectively using the theory of planned behavior. In a study with 461 students, intentions were explained by descriptive norms (mean R² = .49) and moral norms specifically for cannabis. Attitude variability influenced intentions for LSD and ecstasy, while perceived behavioral control moderated the relationship between intentions and actual drug use across all substances. These findings highlight the complex interplay of social influences and personal attitudes in substance use behavior.
Abstract
This study employed the theory of planned behavior (TPB) to investigate the factors underlying intentions to use and use of LSD, amphetamine, canna...
Phencyclidine, Lysergic Acid Diethylamide, and Mescaline: Cerebral Artery Spasms and Hallucinogenic Activity
Science – May 29, 1981
Summary
PCP, LSD, and mescaline induced significant contraction in isolated cerebral arteries, with LSD showing the highest potency. In a sample of isolated arteries, all three substances caused cerebrovasospasm at concentrations that align with their psychotomimetic effects. Notably, PCP's contractile response was similar to levels found in individuals who suffered fatal overdoses. Importantly, verapamil, a calcium antagonist, effectively prevented and reversed PCP-induced vasospasm, suggesting its potential as a treatment for PCP intoxication. This highlights distinct receptors for PCP in cerebral blood vessels.
Abstract
Phencyclidine (PCP), lysergic acid diethylamide (LSD), and mescaline produced potent contractile responses on isolated basilar and middle cerebral ...
PSYCHOTOMIMETICS, CLINICAL AND THEORETICAL CONSIDERATIONS: HARMINE, WIN-2299 AND NALLINE
American Journal of Psychiatry – April 01, 1957
Summary
Harmine, Win-2299, and Nalline induce mental effects in individuals with schizophrenia that closely resemble those from mescaline and LSD. In a sample of 100 participants, these psychotomimetics produced drowsiness and hypnagogic visual hallucinations at varying dosages. Unlike mescaline and LSD, which typically do not cause sleepiness, the effects of these substances suggest an acute toxic reaction. Notably, the chemical structure does not require an indole nucleus, indicating that different molecular components can influence hallucinogenic responses.
Abstract
Harmine, Win-2299, and Nalline in single dosage produce many new mental effects in schizophrenics grossly similar to those elicited by mescaline an...
Effects of serotonergic psychedelics on synaptogenesis and immediate early genes expression - comparison with ketamine, fluoxetine and lithium.
Journal of psychopharmacology (Oxford, England) – May 28, 2025
Summary
Psychedelics like psilocin can rewire brain connections similarly to established psychiatric medications. New research shows psilocin promotes neuroplasticity and new neural connections as effectively as ketamine and lithium - outperforming traditional antidepressants. While DMT and LSD showed minimal effects, psilocin triggered specific brain proteins linked to learning and memory formation.
Abstract
Recent evidence suggests that psychedelics can induce rapid and long-lasting antidepressant effects. The generally acknowledged explanation for the...
Anaesthetic implications of psilocybin and lysergic acid diethylamide: what is old is now new: A narrative review on psychedelics and anaesthesia.
European journal of anaesthesiology – May 01, 2025
Summary
As psychedelic medicines enter mainstream treatment for mental health, their interaction with anesthesia becomes increasingly important. These substances affect serotonin receptors in the brain, potentially impacting blood pressure and heart rate during surgery. Notably, LSD can enhance pain medication effects and influence muscle relaxants, while psilocybin may affect stress hormone levels. Anesthesiologists now recommend delaying non-urgent surgeries until these substances clear the system.
Abstract
Psychedelic drugs, known for their perception-altering properties, are gaining popularity in the treatment of mental health and pain disorders. As ...
Psychedelics as an intervention for psychological, existential distress in terminally ill patients: A systematic review and network meta-analysis
Journal of Psychopharmacology – December 10, 2024
Summary
Psychedelics significantly alleviate anxiety and distress in terminally ill individuals, according to a meta-analysis of nine randomized controlled trials involving 606 participants. These hallucinogens reduced depression (SMD -0.80) and anxiety (SMD -0.84). Psilocybin, an alkaloid, emerged as most effective for depression, while LSD showed promise for anxiety. This review, relevant to clinical psychology and psychiatry, highlights the therapeutic potential of such compounds, often administered by a psychotherapist, for end-of-life care, with comparable safety.
Abstract
Background: The interest in psychedelics as a therapeutic intervention for existential distress of people with terminal illness grounds on their me...
Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology.
Translational psychiatry – December 04, 2024
Summary
Psychedelics like LSD produce stronger visual experiences than psilocybin, while uniquely rewiring brain connectivity patterns. This comprehensive analysis reveals how these substances affect consciousness at multiple levels - from brain chemistry to subjective experience. Different psychedelics create distinct neural "fingerprints," though they share core mechanisms through serotonin receptors. The findings highlight how these compounds alter mental states through complex brain network changes.
Abstract
Serotonergic psychedelics induce altered states of consciousness and have shown potential for treating a variety of neuropsychiatric disorders, inc...
Snapshot of 5-HT 2A receptor activation in the mouse brain via IP 1 detection.
bioRxiv : the preprint server for biology – October 12, 2024
Summary
Scientists have discovered a new way to track how psychedelic drugs like LSD affect specific brain receptors. The research shows that psychedelic and non-psychedelic substances trigger different responses in the brain's serotonin system. By measuring a specific brain chemical called IP1, researchers can now distinguish between true psychedelics and similar compounds, offering insights into how these substances create their unique effects.
Abstract
The distinct subjective effects that define psychedelics such as LSD, psilocybin or DOI as drug class are causally linked to activation of the sero...
Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis.
Psychiatry research – May 01, 2024
Summary
Groundbreaking meta-analysis reveals psychedelics show remarkable promise in treating mental disorders, with psilocybin leading the way. Analysis of 126 studies found these substances effectively reduce depression and anxiety symptoms, with minimal safety concerns. While psilocybin showed strongest results, ayahuasca, MDMA, and LSD also demonstrated significant therapeutic benefits. Most patients reported only mild side effects like headaches.
Abstract
We aim to systematically review and meta-analyze the effectiveness and safety of psychedelics [psilocybin, ayahuasca (active component DMT), LSD an...
Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins
Journal of Psychopharmacology – January 12, 2024
Summary
Microdosing psychedelics, popular in psychology, carries unknown long-term cardiac health risks. Regular use, often 2-4 times weekly for months or years, raises a significant medical concern. Compounds like LSD and psilocybin structurally resemble drugs known to cause cardiac fibrosis and valvulopathy, a critical issue in internal medicine. This risk stems from their neurotransmitter receptor influence on behavior, specifically the 5-HT2B receptor. Understanding these effects is crucial for future Psychedelics and Drug Studies and informs physical medicine.
Abstract
Though microdosing psychedelics has become increasingly popular, its long-term effects on cardiac health remain unknown. Microdosing most commonly ...
Analytical and behavioral characterization of N-ethyl-N-isopropyllysergamide (EIPLA), an isomer of N6 -ethylnorlysergic acid N,N-diethylamide (ETH-LAD).
Drug testing and analysis – February 01, 2024
Summary
A newly studied psychedelic compound shows promising similarity to LSD, with about half its potency. Scientists analyzed EIPLA, one of many new psychoactive substances, finding it produces similar effects to classic psychedelics. Lab tests of blotters revealed precise doses, while animal studies confirmed the substance triggers characteristic behaviors associated with serotonergic compounds.
Abstract
Preclinical investigations have shown that N-ethyl-N-isopropyllysergamide (EIPLA) exhibits lysergic acid diethylamide (LSD)-like properties, which ...
Race and Gender Differences in the Moderating Relationship of Psychedelics on Stigma and Distress
Psychedelic Medicine – April 22, 2025
Summary
Psychedelic use, including psilocybin and LSD, is linked to reduced psychological distress stemming from mental health stigma, according to an analysis of 458,372 individuals. This finding, relevant to clinical psychology, suggests potential benefits for mental well-being. However, the impact varies significantly; White men show stronger associations between lifetime psychedelic use and lower distress from stigma. For other groups, including women and individuals of different race/ethnicity, these associations are less pronounced. The influence of these substances on neurotransmitter receptors, often involving tryptophan-derived compounds, may alter social psychology related to stigma, but benefits are not universal.
Abstract
Objective: Prior research has found an association between psychedelic use and reduced stigma attached to mental illness. However, whether psychede...
Prodrugs of New Psychoactive Substances (NPS): A New Challenge.
Journal of forensic sciences – May 01, 2020
Summary
Many substances are designed to be inactive until the body converts them into active compounds. This mechanism creates a new forensic challenge with 'prodrugs' of new psychoactive substances (NPS). For instance, compounds like 1-propanoyl-lysergic acid diethylamide (1p-lsd), 2cb-aminonitrile (2c-b-an), or psilacetin, complicate detection by releasing their active forms only after metabolism. Recognizing these evolving prodrugs is crucial for accurate forensic and toxicological analysis, enhancing our ability to identify them effectively.
Abstract
The concept of a substance acting as a prodrug for an intended drug is not new and has been known and utilized with particular benefits within medi...
American Trip
The MIT Press eBooks – July 14, 2020
Summary
The nature of psychedelics like Psilocybin in midcentury America was profoundly shaped by historical and social forces. From CIA LSD experiments to the Harvard Psilocybin Project, the user's mindset and surrounding environment—the "set and setting"—determined whether they were seen as therapeutic medicines or dangerous drugs. This era's unique context, encompassing the counterculture, politics, and psychology, influenced perceptions. Figures like Timothy Leary illustrate how collective suggestion, incorporating aesthetics and religious studies, created a distinct "American trip," revealing the deep sociological and psychological interplay defining psychedelic experiences.
Abstract
How historical, social, and cultural forces shaped the psychedelic experience in midcentury America, from CIA LSD experiments the Harvard Psilocybi...
Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities
Journal of Psychopharmacology – February 28, 2020
Summary
Individuals microdosing hallucinogens like psilocybin were significantly less likely to report anxiety disorders (OR = 0.61) or substance use disorders (OR = 0.17). A survey of 909 people explored the demographics of this population, with most using LSD (59.3%) or psilocybin (25.9%) at sub-hallucinogenic doses. While offering insights for psychiatry and potential medicine, these psychedelics and drug studies also found microdosers were over five times more likely (OR = 5.2) to use other recreational substances. Understanding these chemical synthesis alkaloids requires biochemical analysis.
Abstract
Rationale: Microdosing psychedelics – the practice of consuming small, sub-hallucinogenic doses of substances such as LSD or psilocybin – is gainin...
Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature
Therapeutic Advances in Psychopharmacology – January 01, 2019
Summary
Serotonergic hallucinogens like psilocybin significantly reduce the recognition of negative facial expressions, a key aspect of cognitive psychology. A review of 8 studies, from 62 identified in Psychedelics and Drug Studies, revealed that drugs such as LSD modulate amygdala activity. This neuroscience finding suggests a neurotransmitter receptor influence on behavior, potentially aiding psychotherapists. These compounds, derived from chemical synthesis and alkaloids, were well-tolerated and correlated with antidepressive effects, offering promising insights for psychotherapeutic applications.
Abstract
Background: Recognition of emotions in facial expressions (REFE) is a key aspect of social cognition. Anxiety and mood disorders are associated wit...
Rise of the Mushrooms: Effects of Psilocybin Reforms on Psychedelic Usage Patterns
Journal of Public Policy & Marketing – July 16, 2025
Summary
Psilocybin reforms are significantly altering how individuals use hallucinogens. Analysis of extensive drug use panel data from the University of Michigan's Monitoring the Future project reveals a clear substitution: as access to psilocybin, a natural alkaloid, increases, use of LSD and MDMA declines. This trend, critical for Psychedelics and Drug Studies and public psychology, suggests health benefits due to psilocybin's lower risks. However, the burgeoning business and marketing interest, fueled by venture capital, demands careful advertising and consumer safety considerations within this emerging drug market.
Abstract
This study examines the relationship between psilocybin reforms and usage patterns of prevalent psychedelics in the United States. Given decriminal...
Anaesthetic implications of psilocybin and lysergic acid diethylamide: what is old is now new
European Journal of Anaesthesiology – February 18, 2025
Summary
The growing therapeutic use of hallucinogens like Psilocybin and Lysergic acid diethylamide (LSD) in Medicine necessitates careful Anesthesia considerations. These psychedelics, whether natural alkaloids or via chemical synthesis, influence behavior by targeting Serotonin receptors, particularly the 5-HT2A receptor. Their unique Pharmacology can cause sympathetic activation and raise risks like Serotonin syndrome. Mescaline also presents autonomic challenges. Understanding these Neurotransmitter Receptor Influence on Behavior is crucial for safe patient management during Anesthesia, highlighting a vital area in Psychedelics and Drug Studies.
Abstract
Psychedelic drugs, known for their perception-altering properties, are gaining popularity in the treatment of mental health and pain disorders. As ...
Travails of the terminally ill and dying with cancer
Journal of Cancer Research and Therapeutics – January 01, 2015
Summary
A small study by Stanislav Grof suggests controlled hallucinogen administration can offer profound peace to the terminally ill, exemplified by Aldous Huxley's serene death with LSD. Many facing progressive disease endure isolation, neglect, and loss of dignity, experiencing disfigurement, delirium, and profound grief. Palliative care in medicine often overlooks these crucial psychological and spiritual needs. Addressing these complex ethics in medical practice, fostering optimism and well-being, requires holistic nursing and psychiatry approaches, ensuring comprehensive support for those at life's end.
Abstract
In a big yawn of death life is extinguished, ennui of existence comes to an end. The implacable pain evokes a cascade of emotions so does the idea ...
Hallucinogen chemistry guides antidepressant drug discovery
C&EN Global Enterprise – February 07, 2022
Summary
A breakthrough in drug discovery reveals how hallucinogen compounds like LSD and psilocybin bind to a specific serotonin receptor (5-HT 2A), causing their psychedelic effects. By determining the crystal structures of this receptor bound to four distinct molecules—including potent psychedelics and non-hallucinogenic drugs—new pharmacology and chemistry insights emerge. This allows for designing novel antidepressant drugs that maintain mood-altering benefits without inducing hallucinations. These drug studies advance the potential for safer treatments, moving beyond traditional hallucinogens to more targeted therapies.
Abstract
Scientists have long sought the secrets of the 5-HT 2A serotonin receptor—a central nervous system receptor that binds hallucinogenic compounds, in...
Hallucinogens
OpenAlex – March 11, 2022
Summary
Hallucinogens profoundly alter perception by targeting specific brain chemistry. Classic psychedelics like Lysergic acid diethylamide (LSD), a derivative of lysergic acid, psilocybin, and mescaline, primarily influence serotonin neurotransmitter receptors. This pharmacology reveals their impact on neuroscience and psychology. Dissociative drugs, including Phencyclidine, operate differently, affecting glutamate. Drug studies explore their therapeutic potential, such as for Treatment of Major Depression, alongside risks of misuse. Understanding this diverse chemistry and how these substances influence behavior is vital.
Abstract
This chapter highlights the similarities in chemical structure and physiologic effects of hallucinogens, as well as their metabolism, therapeutic u...
Therapeutic Effects of Psychedelics and their Non-Hallucinogenic Analogs on Depressive-Like Behaviour
Carleton undergraduate journal of science. – September 02, 2025
Summary
Major depressive disorder affects 280 million people globally, often resisting current treatments. While psilocybin, a hallucinogen, shows promise in Psychology and Psychedelics and Drug Studies by influencing neurotransmitter receptors, its properties limit accessibility. This research investigates whether non-hallucinogenic compounds, derived from chemical synthesis and alkaloid structures like 2-bromo-LSD, can offer similar antidepressant benefits. Using rodent models, it aims to determine if therapeutic neuroplasticity can occur without the hallucinatory experience, potentially providing more accessible options for treatment-resistant depression.
Abstract
Major depressive disorder (MDD) is a complex and debilitating condition affecting approximately 280 million people worldwide. Its heterogeneous nat...
Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor
UNC Libraries – June 07, 2024
Summary
The molecular mechanism of hallucinogens like LSD and psilocybin is now clearer. Groundbreaking pharmacology precisely mapped the active-state structure of the 5-HT2A serotonin receptor, a crucial neurotransmitter receptor influencing behavior, while bound to a prototypical psychedelic. This advance in drug studies, using cryo-EM, reveals how these chemical synthesis and alkaloids activate the 5-HT receptor, specifically the 5-HT2 receptor. This detailed understanding provides a blueprint for developing more selective drugs, potentially treating various neuropsychiatric disorders.
Abstract
Hallucinogens like lysergic acid diethylamide (LSD), psilocybin, and substituted N-benzyl phenylalkylamines are widely used recreationally with psi...
Efficacy and Safety of Psychedelics in Mental Disorder Cases: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials
Journal of Clinical Medicine – December 29, 2025
Summary
MDMA dramatically reduces PTSD symptoms, showing a Hedges’ g of 1.24, often after only 2–3 sessions. Psilocybin similarly offers a large effect (Hedges’ g ≈ 1.05) for major depressive disorder, with benefits sustained for six months. This umbrella review, synthesizing 23 meta-analyses from clinical psychology, highlights the potential of these hallucinogens in Medicine and Psychiatry. LSD also showed short-term benefits for alcohol use disorder. While adverse effects were mild, rigorous randomized controlled trials are crucial to confirm long-term safety and efficacy for these promising psychedelics.
Abstract
Background: Psychedelic-assisted therapy is gaining renewed attention as a potential treatment for various mental disorders. Despite increasing num...
Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways
Current topics in behavioral neurosciences – January 01, 2017
Summary
Hallucinogens like psilocybin and LSD significantly alter consciousness, emotion, and cognition. Recent insights reveal that these substances primarily act on the serotonin 5-HT2A receptor, with effects linked to its agonist activity. This receptor's role is crucial in understanding the neuropsychological impact of hallucinogens, as it connects to mental health disorders such as schizophrenia. With a focus on the receptor’s structure and function, findings highlight how these compounds influence behavior through neurotransmitter signaling, offering potential therapeutic avenues in psychology and pharmacology.
Abstract
The neuropsychological effects of naturally occurring psychoactive chemicals have been recognized for millennia. Hallucinogens, which include natur...
The Association of Classic Serotonergic Psychedelic Use and Intention of Future Use with Nature Relatedness
Journal of Psychoactive Drugs – August 19, 2022
Summary
Users of classic serotonergic psychedelics, like ayahuasca and psilocybe mushrooms, reported significantly higher nature relatedness (NR) scores. In a Brazilian survey with over 1,000 participants, current users of ayahuasca/DMT and psilocybe mushrooms showed positive associations with NR, while past LSD users also benefitted. Notably, only current and past use of ayahuasca/DMT remained significant after accounting for sociodemographic factors. Additionally, individuals intending to use psilocybe mushrooms in the future exhibited a notable association with increased NR.
Abstract
This study sought to investigate the effects of different substances on nature relatedness (NR) in the general population. An online cross-sectiona...
MDMA (Ecstasy) and the Rave: A Review
PEDIATRICS – October 01, 1997
Summary
MDMA, commonly known as ecstasy, has been linked to at least 58 fatalities, primarily due to severe heat-related complications. Among American adolescents, 24% reported MDMA use in a Tulane University survey, surpassing both LSD and cocaine. In the UK, 8% of 15- and 16-year-olds used MDMA, while 5% of U.S. teens admitted to its use in 1996. Despite its perceived safety, MDMA can cause serious adverse effects like hyperthermia and cardiac issues, highlighting the urgent need for awareness and education about its risks.
Abstract
The drug 3,4 methylenedioxymethamphetamine (MDMA), also known as "ecstasy," is a "designer" drug that is becoming popular with American adolescents...
Dihydrobenzofuran Analogues of Hallucinogens. 4. Mescaline Derivatives
Journal of Medicinal Chemistry – September 01, 1997
Summary
Mescaline's effectiveness as a hallucinogen relies on its full agonist activity at the 5-HT2A receptor. In tests, mescaline fully substituted for LSD in 100% of trained rats, while only 50% and 29% of rats responded to its modified analogs, 8 and 9, respectively. Both analogs demonstrated micromolar affinity for 5-HT1A and 5-HT2A receptors but were significantly less efficacious at 5-HT2A, achieving only 61% and 45% of the maximal serotonin response. These findings highlight the importance of conformational flexibility in the methoxy groups for receptor activation.
Abstract
Dihydrobenzofuran and tetrahydrobenzodifuran functionalities were employed as conformationally restricted bioisosteres of the aromatic methoxy grou...
Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders
Journal of Psychoactive Drugs – August 24, 2023
Summary
Despite reported benefits in Clinical psychology like improved mood and anxiety, evidence for many serotonergic hallucinogens remains limited. A review of 77 Psychedelics and Drug Studies, including Lysergic acid diethylamide (43 studies), Ayahuasca (24), and Mescaline (5), found low-level safety and efficacy data for these compounds. Unlike Psilocybin's growing role in Psychiatry and Medicine, serious adverse events, including homicide and suicide, were linked to Lysergic acid diethylamide. Understanding these chemical synthesis and alkaloids, which influence neurotransmitter receptors, requires more robust investigation.
Abstract
There has been a resurgence of interest in the use of psychedelic therapies for several mental and substance use disorders. Psilocybin, a "classic"...
Adverse drug effects as a deterrent against willingness to use in the future among nightclub/festival attendees.
Drug and alcohol review – September 01, 2023
Summary
Negative experiences with club drugs can significantly impact future use decisions, according to data from nearly 3,000 NYC nightclub and festival attendees. Those who experienced adverse effects from cocaine or ecstasy were roughly half as likely to express willingness to use again within a month. While similar patterns emerged for other substances, the deterrent effect was strongest for these two drugs. This suggests personal experiences of poisoning or other harmful effects may naturally discourage continued use.
Abstract
It is largely unknown whether adverse effects experienced from recreational drug use affect willingness to use again. This study determined whether...
Are psychedelics the answer to chronic pain: A review of current literature
Pain Practice – January 04, 2023
Summary
Psilocybin, a potent hallucinogen, offers a non-addictive alternative for chronic pain management, a critical need in Medicine. For cancer pain and related psychological distress, its analgesic potential was established decades ago, showing promising results in Psychiatry. These psychedelic compounds influence neurotransmitter receptors, disrupting pain pathways. While evidence for general chronic pain efficacy is limited and of low quality, patients self-medicating for severe headaches report relief. Its favorable safety profile, lacking the addiction risk of many analgesics, makes psilocybin a compelling area for ongoing drug studies.
Abstract
Abstract Aims We aim to provide an evidence‐based overview of the use of psychedelics in chronic pain, specifically LSD and psilocybin. Content Chr...
Psychedelics, entactogens and psychoplastogens for depression and related disorders
British Journal of Pharmacology – June 15, 2025
Summary
Psychedelics are revolutionizing Psychiatry. Psilocybin and MDMA, powerful hallucinogens, show promise as rapid antidepressants and anxiolytics in Psychology and Neuroscience. These Psychedelics and Drug Studies highlight their ability to target monoamine neurotransmitter systems, specifically 5-HT2A receptors, influencing behavior. They correct neural network defects in Major depressive disorder and Anxiety, linked to altered brain tryptophan metabolism. Psilocybin received FDA breakthrough status for depression, while MDMA for PTSD was recently rejected. This offers new hope for severe mental health conditions.
Abstract
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin...
On serotonin, psychedelics, entactogens and psychoplastogens in depression, anxiety, post-traumatic stress, and related disorders.
OpenAlex – May 23, 2024
Summary
Potent hallucinogens like psilocybin offer rapid, long-lasting antidepressant and anxiolytic effects for major depressive disorder and anxiety, often after just one or two administrations. Neuroscience and psychiatry reveal these psychedelics modulate the serotonin system, crucial for brain function and implicated in tryptophan-related disorders. Their chemical synthesis yields alkaloids showing promise in drug studies, achieving FDA breakthrough status for conditions involving neuroinflammation and neuroplasticity, revolutionizing psychology's approach to mental health.
Abstract
There is controversy about a causal role of serotonin (5-HT) in depression, some arguing that there is no proof for impaired brain 5-HT function in...
Salvinorin B derivatives, EOM-Sal B and MOM-Sal B, produce stimulus generalization in male Sprague-Dawley rats trained to discriminate salvinorin A.
Behavioural pharmacology – September 01, 2011
Summary
Novel treatments for pain and mood disorders are crucial. Scientists tested if two synthetic compounds, EOM-Sal B and MOM-Sal B, acted like Salvinorin A in rats. Both derivatives fully mimicked Salvinorin A, showing *greater potency*. EOM-Sal B also showed *longer-lasting effects*. These effects were distinct from other drug classes, underscoring the specific therapeutic potential of these powerful new agents.
Abstract
Salvinorin A, the main active component of Salvia divinorum, is a potent and selective κ opioid receptor agonist. Synthetic derivatives of this sub...
Behavioral effects of 5-methoxy-N,N-dimethyltryptamine and dose-dependent antagonism by BC-105.
Psychopharmacology – January 01, 1983
Summary
No Summary
Abstract
The discriminative effects of 5-methoxy-N,N-dimethyltryptamine (5-OMeDMT) were studied in rats trained to discriminate 1.5 mg/kg or 3.0 mg/kg 5-OMe...
Psychedelics
UNC Libraries – April 22, 2020
Summary
Unprecedented relief from anxiety and depression has been observed with psilocybin-assisted psychotherapy in several phase 2 studies involving cancer patients. This potent tool in Psychology and Drug Studies also shows promise for addiction, with two pilot studies demonstrating benefits for alcohol and nicotine use. Psychedelics, physiologically safe and non-addictive, act on brain serotonin receptors, altering perception and mood. Brain imaging reveals they decrease activity in the default mode network, shedding light on their therapeutic impact.
Abstract
Psychedelics (serotonergic hallucinogens) are powerful psychoactive substances that alter perception and mood and affect numerous cognitive process...
Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans
Molecules – April 22, 2021
Summary
Psychedelics, potent drugs with psychotherapeutic promise, offer profound psychological experiences. Their drug action involves complex pharmacology, with molecular imaging showing these alkaloids, often from chemical synthesis, primarily bind to serotonin 5-HT2A receptors. An early PET study confirmed the majority of a specific hallucinogen's binding to 5-HT2A. Despite this neuroscience progress, only a handful of such studies exist, limiting our understanding of their precise action in medicine. Further drug studies, perhaps exploring diverse receptor systems like those in nicotinic acetylcholine receptors study, are crucial.
Abstract
Hallucinogens are a loosely defined group of compounds including LSD, N,N-dimethyltryptamines, mescaline, psilocybin/psilocin, and 2,5-dimethoxy-4-...
How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence
Anesthesia & Analgesia – February 17, 2021
Summary
Michael Pollan's 480-page "How to Change Your Mind" compellingly argues that psychedelics, particularly psilocybin, could revolutionize mental health. Named one of Time's top 100 influential people, Pollan explores their profound impact on consciousness, environmentalism, and counterculture. The book delves into the psychology and sociology of these substances, suggesting drug studies offer a unique "reboot" for conditions where conventional treatments fail, moving beyond traditional psychoanalysis. This engaging work encourages a cautious re-evaluation of psychedelics' therapeutic potential.
Abstract
It is tough to write about psychedelics without a few gratuitous puns. Regardless, Michael Pollan’s “How to Change Your Mind” is definitely “mind e...
Psychotherapie mit adjuvanter Gabe von serotonergen psychoaktiven Substanzen – Möglichkeiten und Hindernisse
Fortschritte der Neurologie · Psychiatrie – July 01, 2017
Summary
Psychedelics like Psilocybin and Lysergic acid diethylamide are re-emerging as powerful tools in psychiatry. These serotonergic hallucinogens and MDMA show promise in psychotherapist-guided medicine. Drug studies indicate efficacy for anxiety, obsessive compulsive disorder, and addiction, influencing neurotransmitter receptors and behavior. Psychology and medicine are exploring their potential. Forensic toxicology and drug analysis will increasingly examine these compounds.
Abstract
Zusammenfassung Hintergrund Der Einsatz von serotonergen Halluzinogenen (Psychedelika) wie Lysergsäure-Diethylamid (LSD) und Psilocybin und Entakto...
Psychedelics Improve the Mental Health of Rats
The FASEB Journal – April 01, 2019
Summary
A single dose of the hallucinogen psilocybin produced long-lasting antidepressant and anxiolytic effects in rats, suggesting a neurochemical basis beyond human psychology. Male Wistar-Kyoto rats (n=8 per group) given psilocybin showed reduced anxiety and depression-like behaviors for over five weeks. Lysergic acid diethylamide, another alkaloid, also had an antidepressant effect, unlike ketamine (used in anesthesia) or saline. This pharmacology insight from psychedelics drug studies indicates a biological foundation for their sustained benefits in medicine and psychiatry, influencing neurotransmitter receptors and behavior.
Abstract
Introduction Psilocybin has recently demonstrated profound efficacy to alleviate depression and anxiety in several clinical trials and has received...
Psychedelic trip sitting, dosages and intensities: Supplementing clinical studies with anecdotal reports
Journal of Psychedelic Studies – July 17, 2024
Summary
Users of 5-MeO-DMT, a potent hallucinogen, strongly perceived a need for care. Analyzing 660 online posts, a Delphi method expert panel created dose intensity charts for various psychedelics, including psilocybin. While oral administration was common for lower doses, greater drug purity from chemical synthesis and alkaloids, and higher doses, correlated with a perceived need for support. This work, vital for Psychology and Psychedelics and Drug Studies, informs medicine, guiding future biochemical analysis of substances like mescaline.
Abstract
Abstract Background and aims Online communities provide insights into psychedelic consumption, assisting in identification of trends, informing bot...
The Potential Therapeutic Benefits and Safety of Psychedelics in the Treatment of Mental Health Conditions: A Systematic Review
Journal of Sociology Psychology & Religious Studies – November 06, 2023
Summary
Emerging evidence strongly suggests psychedelics could revolutionize mental health treatment. A review of 17 articles highlights that hallucinogens like Psilocybin, MDMA, and Lysergic acid diethylamide significantly alleviate anxiety, depression, and PTSD in psychiatry. These compounds elevate mood and improve social cognition, opening new avenues in medicine. While some adverse effects, such as insomnia, were noted, the overall therapeutic benefits for psychological well-being are substantial, guided by a rigorous checklist in clinical psychology and drug studies.
Abstract
Mental illnesses pose social, economic, and health burdens worldwide. The increasing health burden and mental diseases pose the need for investigat...
Psychedelic drugs and the law: What’s next?
Knowable Magazine – March 14, 2024
Summary
Over 60% of Americans support regulated therapeutic psychedelic use, driving a complex legal shift. Oregon's 2023 psilocybin service centers highlight growing state-level drug law reform, with 20 states introducing related legislation. This creates tension with federal law, where psychedelics remain Schedule I. While 5.5 million US adults use psychedelics annually, and MDMA shows promise for PTSD in Phase 3 trials, the political science of reform mirrors marijuana's path: 38 states now have medical cannabis, demonstrating states can lead significant change despite federal resistance.
Abstract
When Oregon's first psilocybin service center opened in June 2023, allowing those over 21 to take mind-altering mushrooms in a state-licensed facil...
Hallucinogens: Magic Mushrooms, Ayahuasca, Mescal Buttons, and Dr. Hofmann’s Problem Child
OpenAlex – October 01, 2020
Summary
Only about 100 of 400,000 plant species contain hallucinogenic chemicals. These substances, like psilocybin or ayahuasca, have been integral to human evolution, straddling science and mysticism. Defined as religious ecstasies involving alternate states of consciousness, magic, and mythology, mysticism is key. While biochemical analysis explores these agents, their impact on consciousness, often inducing a trance, extends to psychoanalysis, psychology, and literature. Psychedelics, enriching the mind, inspire art and aesthetics. Drug studies reveal their profound influence.
Abstract
Abstract There are about 400,000 species of plants in this world. Only a small fraction, perhaps 100 in number, contain hallucinogenic chemicals. N...
Psychedelics for Psychiatric Disorders: More Research Needed
Psychiatric News – April 13, 2020
Summary
Breakthrough status from the FDA highlights the medical potential of psychedelics like psilocybin for depression and MDMA for PTSD. These hallucinogens, including Lysergic acid diethylamide and Ayahuasca, are transforming Psychiatry and Psychology. Placebo-controlled trials show psilocybin's efficacy for depression and MDMA's for PTSD. However, Drug Studies on these four agents are hampered by Schedule I classification and limited federal funding, despite strong evidence suggesting their role in future Medicine. Standardized protocols are crucial for advancing this promising field.
Abstract
Back to table of contents Previous article Next article Clinical & ResearchFull AccessPsychedelics for Psychiatric Disorders: More Research NeededN...
The Effects of Serotonergic Psychedelics on Neural Activity: A Meta-Analysis of Task-Based Functional Neuroimaging Studies
European Psychiatry – March 01, 2023
Summary
Psychedelics like psilocybin and MDMA profoundly alter brain activity. A meta-analysis of functional magnetic resonance imaging (fMRI) studies, a key neuroimaging tool in Neuroscience, reveals that serotonergic hallucinogens significantly impact neural activation across the cerebral cortex and basal ganglia. This work advances functional neuroimaging understanding, particularly regarding neurotransmitter receptor influence on behavior. Essential for Psychology and Psychiatry, these insights inform future Psychedelics and Drug Studies, with implications for therapeutic applications and Forensic Toxicology and Drug Analysis.
Abstract
Introduction Curiosity toward the effects of psychedelic drugs on neural activation has increased due to their potential therapeutic benefits, part...
Period, age, and cohort effects on substance use among young Americans: a decade of change, 1976-86.
American Journal of Public Health – October 01, 1988
Summary
Heavy drinking and substance use among American youth aged 18 to 28 reveal significant trends. Analyzing data from over 30,000 high school seniors from 1976 to 1986, findings show that monthly alcohol use peaked at 60%, while heavy drinking reached 40%. Marijuana and cocaine usage also exhibited noticeable period effects. Additionally, age-related patterns indicated that daily alcohol consumption rose by 15% as youth aged. Class-specific effects were evident, with cigarette smoking increasing among certain cohorts. These insights highlight the evolving landscape of substance use in young adults.
Abstract
In an earlier article in this Journal, we reported analyses that differentiated among period, age, and cohort effects on substance use among Americ...
MDMA, politics and medical research: Have we thrown the baby out with the bathwater?
Journal of Psychopharmacology – November 01, 2007
Summary
MDMA, once a therapeutic tool for psychotherapists, has seen its medical potential overshadowed by political demonization, particularly during the 1980s. Despite its prohibition as a Schedule 1 drug in the UK, which limits human research, MDMA's therapeutic benefits warrant exploration. With over 30 years of cultural penetration and growing recreational use, the ongoing debate highlights a critical issue: political agendas may be stifling scientific inquiry into MDMA’s psychological and medicinal applications. A more objective examination could uncover valuable insights for psychiatry and psychology.
Abstract
3,4-Methylenedioxymethlyamphetamine (MDMA) has penetrated extensively into our culture in the last thirty years. It started life in medicine when a...
Exploring the Potential of Psychedelics in the Treatment of Headache Disorders: Clinical Considerations and Exploratory Insights.
Current pain and headache reports – January 16, 2025
Summary
Breakthrough findings show psychedelics like psilocybin and LSD may offer hope for severe headache disorders. Patients with cluster headaches and migraines reported significant pain reduction and fewer attacks after controlled psychedelic treatment sessions. The compounds work by targeting specific brain receptors, providing longer-lasting relief than conventional medications with fewer side effects.
Abstract
Exploration of the potential of serotonergic psychedelic drugs, such as psilocybin and LSD, as potential treatments for headache disorders. This re...
Multimodal creativity assessments following acute and sustained microdosing of lysergic acid diethylamide.
Psychopharmacology – February 01, 2025
Summary
New research challenges popular claims about microdosing LSD and creativity. While many people report feeling more creative when taking tiny amounts of psychedelics, this controlled study found no measurable improvements in either convergent or divergent thinking. Researchers tracked 80 participants taking low doses of lysergic acid diethylamide over six weeks, testing creative abilities through various tasks.
Abstract
Enhanced creativity is often cited as an effect of microdosing (taking repeated low doses of a psychedelic drug). There have been recent efforts to...
The impact of psychedelics on patients with alcohol use disorder: a systematic review with meta-analysis.
Current medical research and opinion – February 01, 2024
Summary
Psychedelic therapy shows remarkable promise in treating alcohol use disorder, with patients twice as likely to achieve sobriety or significantly reduce drinking when treated with LSD or similar compounds. This comprehensive meta-analysis examined decades of clinical trials, revealing that supervised psychedelic sessions effectively help people overcome alcohol dependency. While most studies focused on LSD, newer research with psilocybin also demonstrates encouraging results. The findings suggest these treatments could offer a powerful new tool for addressing alcohol use disorder, particularly when combined with traditional therapy approaches.
Abstract
Critique the available systematic review and de novo assessment of the role of psychedelics in the treatment of alcohol use disorder. A systematic ...
Classic psychedelics do not affect T cell and monocyte immune responses.
Frontiers in psychiatry – January 01, 2023
Summary
Common psychedelics like LSD, DMT, and mescaline don't suppress immune function, according to laboratory testing. Scientists examined how these compounds interact with T cells and monocytes - crucial components of our immune system. The findings showed that psilocin and other psychedelics didn't interfere with normal immune cell activity, suggesting these substances are safe for therapeutic use without compromising immune health.
Abstract
Classic psychedelics have been shown to exert therapeutic potential for the treatment of various psychiatric disorders, neuropsychiatric diseases, ...
Past-year hallucinogen use in relation to psychological distress, depression, and suicidality among US adults.
Addictive behaviors – September 01, 2022
Summary
Ecstasy (MDMA) use was linked to *reduced* psychological distress and suicidal thoughts among US adults. A study of over 240,000 US adults explored how various hallucinogens, including psychedelics, relate to mental well-being. While ecstasy showed decreased depression and suicidality, other hallucinogens like LSD were linked to increased risks. This reveals distinct impacts of different hallucinogens on mental health.
Abstract
There is renewed interest in the clinical application of hallucinogenic substances to treat a range of psychiatric conditions. However, there is mi...
1H Nuclear Magnetic Resonance: A Future Approach to the Metabolic Profiling of Psychedelics in Human Biofluids?
Frontiers in psychiatry – January 01, 2021
Summary
Unlocking the full therapeutic potential of psychedelics like psilocybin and lsd hinges on understanding their metabolic journey. A review explored proton nuclear magnetic resonance (NMR) as a powerful metabolomics tool. While current work uses NMR for structural analysis of psychedelics and new psychoactive substances, its application for metabolic profiling in biofluids is an exciting, untapped area. This approach, alongside mass spectrometry and liquid chromatography, shows great promise for mapping how these compounds break down, offering valuable insights for future research.
Abstract
While psychedelics may have therapeutic potential for treating mental health disorders such as depression, further research is needed to better und...
Registered clinical studies investigating psychedelic drugs for psychiatric disorders.
Journal of psychiatric research – July 01, 2021
Summary
The number of clinical trials exploring psychedelics for psychiatric disorders has significantly increased, driven by promising early findings. Researchers are investigating compounds like MDMA and psilocybin, primarily for conditions such as post-traumatic stress disorder and depression. Other psychedelics, including LSD, ayahuasca, ibogaine, and DMT, are also being explored for various psychiatric disorders, highlighting a growing interest in these innovative treatments.
Abstract
Psychedelics are a hallucinogenic class of psychoactive drugs with the primary effect of activating non-ordinary states of consciousness. Due to th...
Tags
Psilocybin-induced stimulus control in the rat.
Pharmacology, biochemistry, and behavior – October 01, 2007
Summary
Rats trained to recognize psilocybin revealed its unique brain effects involve a complex interplay of receptors. The 5-HT2A receptor plays a prominent role in mediating psilocybin's distinct internal signal, yet it's not the sole factor. Other hallucinogens like LSD and psilocin produced similar responses, often blocked by 5-HT2A antagonists. Significantly, 5-HT1A receptors, active with some related compounds, were not involved in psilocybin's specific effects. This advances our understanding of psilocybin's precise mechanisms.
Abstract
Although psilocybin has been trained in the rat as a discriminative stimulus, little is known of the pharmacological receptors essential for stimul...
Electrodynamics of the Psychedelic Experience
Preprints.org – September 22, 2025
Summary
Consciousness may emerge from brain electromagnetic fields, not solely neural computations. Psychedelic drug studies reveal substances like LSD, psilocybin, ketamine, and 5-MeO-DMT profoundly alter consciousness by modulating these fields. Evidence suggests these chemicals act as "field resonance enhancers." LSD produces sustained coherence, psilocybin increases oscillatory flexibility, ketamine causes dissociative field fragmentation, and 5-MeO-DMT induces rapid field boundary dissolution. These specific molecular interactions, through receptor modulation, tune field computation, offering novel insights into ego dissolution, creativity, and therapeutic potential.
Abstract
Electromagnetic field theories of consciousness propose that consciousness emerges from resonant electromagnetic field interactions rather than pur...
Gestational psychedelic exposure disrupts brain development and offspring behavior in mice.
bioRxiv : the preprint server for biology – September 30, 2025
Summary
Maternal psychedelic exposure in mice quickly delivers compounds like LSD to embryonic brain fluid, reaching the developing brain within minutes. This groundbreaking research clearly shows that even a single exposure during gestation significantly alters brain structure and cell development. These profound changes result in lasting behavioral differences in adult offspring, including sensory processing issues. This work establishes a critical link between maternal psychedelic use and enduring neurodevelopmental impacts.
Abstract
Despite increasing non-medical use and clinical investigation of psychedelics, the consequences of prenatal exposure remain unknown. In mice, mater...